Genetic polymorphism in the epidermal growth factor receptor gene predicts outcome in advanced non-small cell lung cancer patients treated with erlotinib

Lung Cancer

Volumn 90, Issue 2, 2015, Pages 314-320

  Winther Larsen, Anne ^a   Nissen, Peter Henrik ^a   Jakobsen, Kristine Raaby ^a,b   Demuth, Christina ^a   Sorensen, Boe Sandahl ^a   Meldgaard, Peter ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b AARHUS UNIVERSITY   (Denmark)

Author keywords

EGFR; Erlotinib; Genetic polymorphisms; Survival; TKI; Treatment response

Indexed keywords

DOCETAXEL; ERLOTINIB; PEMETREXED; PLATINUM COMPLEX; EGFR PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR RECEPTOR; PROTEIN KINASE INHIBITOR;

ADULT; ADVANCED CANCER; AGED; ALLELE; ARTICLE; CANCER PATIENT; CONFIDENCE INTERVAL; DIARRHEA; DISEASE CONTROL; DISEASE CONTROL RATE; DNA SEQUENCE; EPIDERMAL GROWTH FACTOR RECEPTOR GENE; FEMALE; GENE; GENETIC VARIABILITY; HAZARD RATIO; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; PRIORITY JOURNAL; PROCEDURES; PROGRESSION FREE SURVIVAL; PROPORTIONAL HAZARDS MODEL; RASH; SINGLE NUCLEOTIDE POLYMORPHISM; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE FREE SURVIVAL; GENETIC POLYMORPHISM; GENETICS; LUNG NEOPLASMS; MIDDLE AGED; MUTATION; RETROSPECTIVE STUDY; TREATMENT OUTCOME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE-FREE SURVIVAL; ERLOTINIB HYDROCHLORIDE; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; POLYMORPHISM, GENETIC; PROTEIN KINASE INHIBITORS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84955242062     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2015.09.003     Document Type: Article

References (27)

1. Sharma S.V., Bell D.W., Settleman J., Haber D.A. Epidermal growth factor receptor mutations in lung cancer. Nat. Rev. Cancer 2007, 7:169-181.
2. Shepherd F.A., Rodrigues Pereira J., Ciuleanu T., Tan E.H., Hirsh V., Thongprasert S., et al. Erlotinib in previously treated non-small-cell lung cancer. N. Engl. J. Med. 2005, 353:123-132.
3. Pao W., Miller V.A., Kris M.G. Targeting the epidermal growth factor receptor tyrosine kinase with gefitinib (Iressa) in non-small cell lung cancer (NSCLC). Semin. Cancer Biol. 2004, 14:33-40.
4. Lynch T.J., Bell D.W., Sordella R., Gurubhagavatula S., Okimoto R.A., Brannigan B.W., et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 2004, 350:2129-2139.
5. Reck M., Popat S., Reinmuth N., De R., uysscher D., Kerr K.M., Peters S. Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 2014, 25(Suppl. 3):iii27-iii39.
6. Zhao N., Zhang X.-C., Yan H.-H., Yang J.-J., Wu Y.-L. Efficacy of epidermal growth factor receptor inhibitors versus chemotherapy as second-line treatment in advanced non-small-cell lung cancer with wild-type EGFR: a meta-analysis of randomized controlled clinical trials. Lung Cancer 2014, 85:66-73.
7. Wheeler H.E., Maitland M.L., Dolan M.E., Cox N.J., Ratain M.J. Cancer pharmacogenomics: strategies and challenges. Nat. Rev. Genet. 2013, 14:23-34.
8. Liu W., Innocenti F., Wu M.H., Desai A.A., Dolan M.E., Cook E.H., et al. A functional common polymorphism in a Sp1 recognition site of the epidermal growth factor receptor gene promoter. Cancer Res. 2005, 65:46-53.
9. Jung M., Cho B.C., Lee C.H., Park H.S., Kang Y.A., Kim S.K., et al. EGFR polymorphism as a predictor of clinical outcome in advanced lung cancer patients treated with EGFR-TKI. Yonsei Med. J. 2012, 53:1128-1135.
10. Liu G., Gurubhagavatula S., Zhou W., Wang Z., Yeap B.Y., Asomaning K., et al. Epidermal growth factor receptor polymorphisms and clinical outcomes in non-small-cell lung cancer patients treated with gefitinib. Pharmacogenomics J. 2008, 8:129-138.
11. Gregorc V., Hidalgo M., Spreafico A., Cusatis G., Ludovini V., Ingersoll R.G., et al. Germline polymorphisms in EGFR and survival in patients with lung cancer receiving gefitinib. Clin. Pharmacol. Ther. 2008, 83:477-484.
12. Ma F., Sun T., Shi Y., Yu D., Tan W., Yang M., et al. Polymorphisms of EGFR predict clinical outcome in advanced non-small-cell lung cancer patients treated with Gefitinib. Lung Cancer 2009, 66:114-119.
13. Zhang L., Yuan X., Chen Y., Du X.-J., Yu S., Yang M. Role of EGFR SNPs in survival of advanced lung adenocarcinoma patients treated with Gefitinib. Gene 2013, 517:60-64.
14. Weber B., Hager H., Sorensen B.S., McCulloch T., Mellemgaard A., Khalil A.A., et al. EGFR mutation frequency and effectiveness of erlotinib: a prospective observational study in Danish patients with non-small cell lung cancer. Lung Cancer 2014, 83:224-230.
15. Therasse P., Arbuck S.G., Eisenhauer E.A., Wanders J., Kaplan R.S., Rubinstein L., et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J. Natl. Cancer Inst. 2000, 92:205-216.
16. Morlan J., Baker J., Sinicropi D. Mutation detection by real-time PCR: a simple, robust and highly selective method. PLoS One 2009, 4:e4584.
17. Sherry S.T., Ward M.H., Kholodov M., Baker J., Phan L., Smigielski E.M., et al. dbSNP: the NCBI database of genetic variation. Nucleic Acids Res. 2001, 29:308-311.
18. Shitara M., Sasaki H., Yokota K., Okuda K., Hikosaka Y., Moriyama S., et al. Polymorphisms in intron 1 of the EGFR gene in non-small cell lung cancer patients. Exp. Ther. Med. 2012, 4:785-789.
19. Liu W., He L., Ramírez J., Krishnaswamy S., Kanteti R., Wang Y.-C., et al. E.G.F.R. functional germline polymorphisms may confer risk for EGFR somatic mutations in non-small cell lung cancer, with a predominant effect on exon 19 microdeletions. Cancer Res. 2011, 71:2423-2427.
20. Sueoka-Aragane N., Imai K., Komiya K., Sato A., Tomimasu R., Hisatomi T., et al. Exon 19 of EGFR mutation in relation to the CA-repeat polymorphism in intron 1. Cancer Sci. 2008, 99:1180-1187.
21. Liu G., Cheng D., Ding K., Le M., aitre A., Liu N., Patel D., et al. Pharmacogenetic analysis of BR. 21, a placebo-controlled randomized phase III clinical trial of erlotinib in advanced non-small cell lung cancer. J. Thorac. Oncol. 2012, 7:316-322.
22. Ichihara S., Toyooka S., Fujiwara Y., Hotta K., Shigematsu H., Tokumo M., et al. The impact of epidermal growth factor receptor gene status on gefitinib-treated Japanese patients with non-small-cell lung cancer. Int. J. Cancer 2007, 120:1239-1247.
23. Parmar S., Schumann C., Rüdiger S., Boeck S., Heinemann V., Kächele V., et al. Pharmacogenetic predictors for EGFR-inhibitor-associated skin toxicity. Pharmacogenomics J. 2013, 13:181-188.
24. Giovannetti E., Zucali P.A., Peters G.J., Cortesi F., D'Incecco A., Smit E.F., et al. Association of polymorphisms in AKT1 and EGFR with clinical outcome and toxicity in non-small cell lung cancer patients treated with gefitinib. Mol. Cancer Ther. 2010, 9:581-593.
25. Nackley A.G., Shabalina S.A., Tchivileva I.E., Satterfield K., Korchynskyi O., Makarov S.S., et al. Human catechol-O-methyltransferase haplotypes modulate protein expression by altering mRNA secondary structure. Science 2006, 314:1930-1933.
26. Kimchi-Sarfaty C., Oh J.M., Kim I.-W., Sauna Z.E., Calcagno A.M., Ambudkar S.V., et al. A silent polymorphism in the MDR1 gene changes substrate specificity. Science 2007, 315:525-528.
27. Sauna Z.E., Kimchi-Sarfaty C., Ambudkar S.V., Gottesman M.M. Silent polymorphisms speak: how they affect pharmacogenomics and the treatment of cancer. Cancer Res. 2007, 67:9609-9612.